SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY Russian patent published in 2024 - IPC C07D498/04 A61K31/424 A61K31/5365 A61K31/553 A61P29/00 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a novel compound having the structure of formula (I-5), or a pharmaceutically acceptable salt thereof, which have the property of inhibiting inflammasome, such as NLRP3 inflammasome. In formula (I-5), R¹⁰⁰ is selected from a group consisting of H, -CN, -C(O)R^3b and C₁-C₆alkyl; R^l is selected from the group consisting of

R^1z is H; each of R^1a, R^1b, R^1c, R^1d, R^1e, R^1f, R^1g and R^1h is independently selected from a group consisting of H, -OR^11a, -NR^11aR^12a, C₁-C₆alkyl or 4-membered heterocyclyl with one ring heteroatom selected from nitrogen; where said 4-member heterocyclyl is not substituted or is substituted with one or more substitutes selected from -OR^11a; R² is selected from a group consisting of 5-member heteroaryl with two ring heteroatoms selected from nitrogen, where said 5-member heteroaryl is not substituted or is substituted with one or more substitutes selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ haloalkyl and -(CH₂)_1-4C₃-C₁₀cycloalkyl; X² is CR^2a ; X³ is N or CR^2c; X⁴ is CR^2d; X⁵ is N or CR^2e; R^2a is H, halogen or -C(O)OR^15a; each of R^2b, R^2c, R^2d, R^2e and R^2f independently represents H, halogen, -OR^17a, -C(O)R^17b, C₁-C₆alkyl or 5-6 membered heteroaryl with one ring heteroatom selected from nitrogen; where C₁-C₆ alkyl and said 5-6-membered heteroaryl are not substituted or are substituted with one or more substitutes selected from the group consisting of -OR_17a and -NR^17aR^18a; or two adjacent R^2b, R^2c, R^2e and R^2f together with atoms to which they are attached, can form C₃-C₁₀ cycloalkyl or 3-7-membered heterocyclyl with one ring heteroatom selected from oxygen, where C₃-C₁₀ cycloalkyl and said 3-7-membered heterocyclyl are not substituted or are substituted with one or more substitutes selected from the group consisting of halogen and C₁-C₆ alkyl; R^11a, R^12a, R^15a, R^17a and R^18a independently in each occurrence are H or C₁-C₈ alkyl; where C₁-C₈ alkyl is unsubstituted or substituted with one or more substitutes selected from the group consisting of halogen, -O-C₁-C₆alkyl and -NH(C₁-C₆alkyl); R^3b and R^17b independently in each case represent -OH or C₁-C₈ alkyl. Invention also relates to a pharmaceutical composition containing said compound.

EFFECT: disclosed are sulfonimidamide compounds as inhibitors of interleukin-1 activity.

24 cl, 6 tbl, 158 ex